Approved at the beginning of 2016, US revenues of the cheaper competitor, Basaglar ... its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba ...

Basaglar will also undercut Sanofi’s longer ... by 21% and Tresiba (insulin degludec) an ultra long-acting insulin, by 28%. The prices that patients will pay depends on their insurance scheme ...

The FDA previously approved two long-acting insulin biosimilars, Mylan Pharmaceuticals’ Semglee in June 2020 and Lilly’s glargine biosimilar, Rezvoglar in December 2021. Merilog is approved as ...

Merilog is available in a 3 mL prefilled pen and a 10 mL vial, joining two long-acting insulin biosimilars approved by the FDA in 2021. Merilog, a rapid-acting human insulin analog, is the first ...

The US FDA has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes.

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...

Merilog also marks the third insulin biosimilar approved in the United States, following two long-acting biosimilars approved in 2021. 1 "The FDA has now approved three biosimilar insulin products to ...

The FDA has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog, to improve glycemic control in patients with diabetes mellitus.

The FDA noted that Merilog is the third insulin biosimilar product to get its approval. In 2021, the agency had approved two long-acting insulin biosimilar products. A biosimilar is a biological ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products approved in 2021 by the FDA. Approval of biosimilar products can ...